Q1 Earnings Forecast for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Exelixis in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the biotechnology company will earn $0.35 per share for the quarter. The consensus estimate for Exelixis’ current full-year earnings is $1.74 per share. Leerink Partnrs also issued estimates for Exelixis’ Q2 2025 earnings at $0.49 EPS, Q3 2025 earnings at $0.60 EPS and Q4 2025 earnings at $0.65 EPS.

EXEL has been the subject of several other reports. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $41.00 to $33.00 in a research report on Friday, January 24th. TD Cowen raised their target price on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Stifel Nicolaus raised their target price on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, October 16th. Truist Financial raised their target price on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $30.00 to $40.00 in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $36.06.

Exelixis Price Performance

Shares of Exelixis stock opened at $33.48 on Friday. Exelixis has a 1 year low of $20.01 and a 1 year high of $37.59. The firm has a market cap of $9.56 billion, a PE ratio of 21.46, a P/E/G ratio of 0.72 and a beta of 0.53. The stock has a fifty day moving average price of $34.39 and a 200-day moving average price of $30.45.

Institutional Trading of Exelixis

Large investors have recently modified their holdings of the business. Principal Securities Inc. boosted its position in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Exelixis during the 4th quarter valued at about $32,000. V Square Quantitative Management LLC purchased a new position in shares of Exelixis during the 3rd quarter valued at about $30,000. Kestra Investment Management LLC purchased a new position in shares of Exelixis during the 4th quarter valued at about $39,000. Finally, UMB Bank n.a. raised its holdings in shares of Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 553 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the sale, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. This trade represents a 10.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Patrick J. Haley sold 41,588 shares of Exelixis stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the sale, the executive vice president now owns 288,665 shares of the company’s stock, valued at approximately $9,918,529.40. This trade represents a 12.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 111,588 shares of company stock worth $3,981,864 in the last quarter. 2.85% of the stock is owned by company insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.